| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
On page 160, there were errors in the text. Here we print the correct text.
doi: 10.1634/theoncologist.2007-0126
Study 3
A placebo-controlled, randomized study that evaluated the effect of epoetin alfa along with iron supplementation on transfusion requirements in children with sarcomas receiving intensive chemotherapy concluded that prophylactic rHuEPO significantly reduced RBC transfusion requirements [28]. In this study, although 24 children were randomized, only 20 patients were deemed evaluable. Of these 20 children, 10 each were randomly assigned to receive either epoetin alfa or a matching volume of placebo (normal saline) for 16 weeks. The dose of rHuEPO was 150 IU/kg three times per week s.c. or i.v. Compared with placebo, children randomized to receive epoetin alfa had significantly fewer RBC [p = .01] and platelet [p = .005] transfusions. However, there was no difference in the number of patients who required any RBC transfusion in the study [EPO group, 9/10; no EPO group, 10/10]. No significant toxic effects of rHuEPO were reported.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |